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Summary:  Nephropathic cystinosis is an autosomal recessive inborn error of 
metabolism characterized by the lysosomal storage of the disulphide amino acid 
cystine. It produces a variety of clinical manifestations including failure to thrive, 
the renal Fanconi syndrome, eye findings, and end-stage renal disease. A variety of 
phenotypes are known; however, the molecular defect underlying any of the forms 
has not yet been identified. Therapy of cystinosis with cysteamine averts the 
otherwise inevitable renal failure, but systemic therapy does not improve the corneal 
keratopathy. A number of presentations in this review detail approaches to gene 
identification, systemic therapy with cysteamine, measurement of cystine, and 
pathophysiological effects at the cellular and clinical level. 
Cystinosis (McKusick 219800) has been known as a clinical entity since the early years of 
this century when Abderhalden noted a child dying of inanition who had curious white 
crystals found in the liver at autopsy (Abderhalden 1903). The pedigree revealed other 
children similarly affected and classical chemical analysis demonstrated that the 
compound found in the liver was cystine. Initially, cystinosis was confounded with the 
genetically unrelated condition cystinuria, and is now known as the most common cause 
of the renal Fanconi syndrome. 
Cystinosis is a multisystemic disease (see Table 1) affecting all organ systems. The 
primary defect that underlies the pathophysiology is lysosomal cystine storage (Schulman 
et al 1969). Lysosomes of affected homozygous patients demonstrate cystine content up to 
100-fold greater than that of unaffected normal individuals. The cause of the cystine 
storage is now known to be a defective transport system for cystine in the lysosomal 
membrane cystine (Gahl et al 1989). Lysosomal accumulation of cystine correlates with 
cell death in ways not yet understood. Cystinosis is inherited as an autosomal recessive 
condition, like most other inborn errors of metabolism, and heterozygotes have been 
shown to have approximately 50% of the cystine transport capacity in their lysosomes of 
that of normal individuals (Gahl et al 1984). Homozygotes demonstrate little or no cystine 
export. Cystine in some tissues forms crystals owing to its insolubility (approximately 
112mg/L at 25°C). 
The tissue first manifesting pathological change is the retina, which has been shown to 
display a salt-and-pepper pattern as early as fetal life. Subsequently, the renal Fanconi 
syndrome develops within the first year of life, with the major clinical findings of polyuria 
accompanied by glucosuria, phosphaturia and aminoaciduria. Recently, Gahl's group has 
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Table 1 Clinical findings in cystinosis 
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Figure 1 Cystine depletion of cystinotic fibroblasts by cysteamine. At time 0, 0.1mmol/L 
cysteamine was added to confluent cultures of cystinotic fibroblasts. At the intervals indicated, 
fibroblasts were harvested and the cystine content was determined by a cystine-binding protein assay 
shown that camitinuria is another concomitant of the renal Fanconi syndrome and this may 
well correlate with the muscle weakness experienced by some patients in later years. 
Over the course of the first decade of life there is a quasilinear decline in renal function 
such that, by age 10 years, renal function is absent and patients must be maintained on 
dialysis or receive a renal transplant. 
Thoene and colleagues demonstrated that addition of cysteamine to cultures of 
cystinotic fibroblasts produced rapid cystine depletion (Thoene et al 1976; see Fig. 1). 
Subsequent studies in several laboratories have demonstrated that the mechanism of action 
involves a disulphide exchange reaction between cysteamine and cystine followed by 
export of the product of the reaction (this is termed the mixed disulphide of cysteamine 
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Figure 2 The mechanism of cystine depletion by cysteamine. Cysteamine reacts with cystine to 
form the mixed disulphide of cysteamine and cystine. This compound is an analogue of lysine and 
is recognized by the intact lysine porter in the lysosomal membrane, leading to cystine depletion 
and cystine) on a normally functioning lysine porter not defective in cystinotic lysosomes 
(see Fig. 2). 
Based on the promising biochemical evidence described above, it seemed reasonable to 
determine whether cysteamine administration would lead to long-term systemic cystine 
depletion and whether this might correlate with stabilized or improved renal function. 
Several long-term clinical trials of cysteamine in patients with cystinosis have been 
conducted. Cysteamine administration does stabilize renal function and improves linear 
growth (Gahl et al 1989). Subsequent studies in the United Kingdom and a second trim in 
the United States confirmed these initial observations, leading to new drug approval for 
cysteamine for the treatment of cystinosis in the United States on 15 August 1994. 
Significant unanswered questions remain with respect to nephropathic cystinosis and its 
milder forms, benign and intermediate. The first question is 'What is the molecular basis 
of cystinosis?' Attempts to define both the chromosomal location of the gene and the gene 
sequence itself are proceeding in the author's laboratory at the University of Michigan and 
with Dr van't Hoff at Guy's Hospital in London in conjunction with Dr Gahl's laboratory 
at the National Institutes of Health. The groups have taken separate approaches. Thoene 
and co-workers are attempting to define the gene by phenotype rescue. In that technique, 
cystinotic fibroblasts are transfected with a human fibroblast cDNA library in a convenient 
plasmid vector (pcDNA III). Following transfection, the cells are placed in selective medium 
containing cystine dimethyl ester (2mmol/L for 20min). It has been found (Pisoni et al 1992) 
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that this exposure is toxic to cystinotic but not to normal fibroblasts. Following exposure to 
cystine dimethyl ester, the cells are then placed in g418 medium to select for the presence 
of the neomycin resistance gene, which is a component of the vector. Cells that emerge 
from this dual selection system are then expanded and the DNA is subjected to PeR using 
primers derived from the vector regions flanking the insert to recover the portion of the 
cDNA library that codes for the cystine transport gene. A number of candidate cDNAs 
have been obtained, some of which show homology to other transporters, which offers 
some', encouragement that the identity of the gene will be discoverable by this technology. 
van't Hoff and colleagues (1994b) have undertaken a linkage study to map the gene for 
cystinosis. They employ 250 evenly distributed markers spaced at approximately 20 
centimorgan intervals. The microsatellite markers are fluorescently labelled and automated 
analysis allows multiple markers to be run on a single gel. Fifteen families have been typed 
with 168 microsatellite markers covering approximately 65% of the genome. The LOD 
scores for 8 chromosomes have been negative. Work continues to define the chromosomal 
location of the lysosomal cystine gene. 
Schneider and colleagues (1995) report on the clinical trials that lead to US FDA new 
drug approval for cysteamine treatment of nephropathic cystinosis (Cystagon ®, Mylan 
Pharmaceuticals, Inc). In particular, they describe a technique that smooths the data on 
renal function to permit a clear delineation between the effects of cysteamine treatment 
and non-treatment on the course of renal failure in cystinosis. 
Henderson and Evans (1994) reported a comparison of leukocyte cystine analysis by 
GC-MS and competitive binding protein assays. A leukocyte pellet was prepared by the 
precipitation of erythrocytes with acid citrate dextran. The pellet was sonicated and then 
frozen. Deuterated cystine, the internal standard, was added prior to assay. Cystine was 
reduced to the monomer cysteine by mixing with tributylphosphine, t-Butyldimethylsilyl 
esters were formed using the reagent MTBSTFA. This was necessary because the cystine 
dimer cannot form silyl derivatives directly. Cysteine and deuterated cysteine were 
quantified by selected-ion monitoring at 378 and 380amu. The assay was linear up to a 
cystine concentration of 100pmol/L, and was found to have good precision with aqueous 
standards. However, it gave very high results with little or no discrimination between 
controls (6.2- 29.2 nmol ½ cys/mg protein, n = 32) and cystinotic patients ( 12.2 - 45.2 nmol 
~A cys/mg protein, n = 9). They concluded that the GC-MS assay as described did not give 
meaningful results and that overstimulation of cystine might be due to measurement of 
cysteine residues from sources other than the cystine dimer. The results of the competitive 
cystine binding assay for cystine in their hands paralleled the published experience for 
sensitivity and the ability to discriminate between homozygotes and normal individuals. 
Skovby and Hertel (1994) reported on the use of growth hormone in cystinosis. Growth 
hormone', was supplied in conjunction with cystamine and standard electrolyte replacement 
therapy. They found that urinary levels of growth hormone were several thousandfold 
elevated and serum levels of IGF1 and mean concentrations of growth hormone in urine 
were low compared to normal control children. They suggest that the growth retardation 
seen in cystinosis could be partly due to the excessive loss of growth hormone in the urine. 
As reported by other authors, they found that treatment with growth hormone dramatically 
increased linear growth. They caution that this also may hasten the onset of relative renal 
failure, as previously suggested (Andersson et al 1992). 
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Pintos-Morell and colleagues (1994) noted that linkage between lysosomal cystine and 
the pathophysiology that occurs in nephropathic cystinosis is not yet understood, and that 
an altered oxidative metabolism in polymorphonuclear cells and monocytes as well as 
changes in oxygen consumption and reabsorption capacity of the renal tubular cells had 
been suggested previously. Since cysteine is a component of the sulphidopeptide- 
leukotrienes LTC 4, LTD 4 and LTE 4, which have potent vasoactive actions and induce 
contractions of renal mesangial cells, they studied leukotriene production in isolated 
polymorphonuclear leukocytes stimulated with the ionophore A23187 in cystinotic 
children, in heterozygotes and controls. They found that the polymorphic leukocytes from 
untreated cystinotic children produced an increased amount of LTC 4 (417+70 vs 
177+30.9pmol per 107 cells compared to controls, p<0.1). Concomitantly, L T B  4 
production was decreased compared to controls, but the total amount of LTA 4 was normal. 
PMNs from cystinotic children treated with cysteamine produced lower amounts of LTC 4 
compared to untreated patients. Cessation of cysteamine treatment for 3 - 4  days resulted 
in an increase in LTC 4 production. They conclude that the findings suggest that the 
metabolic abnormalities in cystinosis may result from the biosynthesis of LTC 4 from 
polymorphonuclear leukocytes. 
van't Hoff and colleagues (1994a) studied the effect of storage of whole blood on 
leukocyte cystine concentration in patients with cystinosis. The diagnosis of many rare 
diseases is hampered by the need to analyse fresh samples, which, given the geographic 
dispersion of the patients involved, leads to logistical difficulties. Currently, the state-of- 
the-art method for measuring cystine is to use the cystine-binding protein assay (see 
above); however, this requires preparation of a mixed leukocyte pellet that is then sent on 
dry ice to the referral laboratory for measurement. Not all clinical laboratories have the 
ability to produce such a pellet in usable fashion, van't Hoff and associates determined that 
storage of whole blood for 24 or 48h in either acid citrate dextran (ACD) or lithium 
heparin tubes had no statistically significant effect on the leukocyte cystine concentration 
compared to control samples isolated immediately by the usual protocol. After 24h they 
found a mean cystine content of 2.35 nmol/mg protein for the controls compared to 2.62 
for ACD and 2.23 for heparin. After 48h, the controls were 2.17, ACD 2.34, and heparin 
2.47. They conclude that sites unable to prepare leukocyte pellets can therefore send whole 
blood, anticoagulated by either method, to a specialized laboratory for assay of leukocyte 
cystine. 
The elevation in serum cholesterol in patients with cystinosis was studied by Hulton and 
colleagues (1994). They measured total serum cholesterol using an enzymatic method in 
25 children with cystinosis over a period of 4 years. An approximately equal male and 
female distribution was found with an age range of 1.8-15.9 years, all of whom were 
predialysis and not yet transplanted. Fifteen children (60%) had serum cholesterol concen- 
trations greater than two standard deviations above the mean, using age-related reference 
data. They found no correlation between cholesterol and age or sex but did find that the 
higher cholesterol concentrations occurred in those who were progressing more rapidly to 
end-stage renal disease. 
van't Hoff and colleagues (1994c) reported on the development of a newly encapsulated 
form of cysteamine for the treatment of cystinosis. Cysteamine, a free thiol, has a noxious 
odour and taste, making it intolerable in approximately 14% of patients to whom it is 
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administered, even though it is understood to be the only effective means of avoiding end- 
stage renal disease in cystinosis. Aqueous cysteamine hydrochloride is particularly 
odoriferous and thus encapsulation is needed. Dr van't  Hoff 's  group undertook a single- 
dose study of a cysteamine capsule in six patients aged 6 - 1 9  years. Three had had renal 
transplant, but stable renal function, none had had cysteamine for seven days prior to the 
study. The capsule represented a cysteamine dose of 15 mg/kg in a poly(ethylene glycol) 
base and was given on an empty stomach. Plasma cysteamine and leukocyte cystine 
concentrations were determined over the subsequent 24h. The cysteamine odour was 
noted in all patients post-dose, but it was felt to be mild and there were no other adverse 
side-effects. The mean leukocyte cystine fell from a pre-dose level of 6.03 to a minimum 
of 1.43 at 3 hours and remained low at 24h (3.03+1.61nmol ~A cystine/mg protein). 
Plasma cysteamine determined in four patients showed a biphasic absorption profile with 
a mean peak of 29flmol/L at 30rain, and a second peak of 23/lmol/L at 90rain. They 
conclude that the systemic bioavailability of the capsule is 50%. 
Vilaseca and colleagues (1994) reported that a biochemical response does not always 
correlate with clinical benefit in late-treated nephropathic cystinosis. They reported on 
three patients, a 3-year-old boy and his 1-year-old sister, and an unrelated 2-year-old girl 
diagnosed with nephropathic cystinosis on the basis of elevated leukocyte cystine content. 
They were begun on therapy after renal failure had intervened with a GFR of 19.4 and 
25.3 ml/min per 1.73 m 2 in the first two cases. The third patient did not have renal failure 
but had tubular nephropathy. Carnitine was found to be low in all three children. 
Cysteamine treatment of 50 -60mg/kg  per day of free base and carnitine was started one 
year after diagnosis. The mean cystine depletion from leukocytes was 85% for two years 
and plasma carnitine was normalized. They note, however, that proteinuria and the 
excretion of other compounds due to the renal Fanconi syndrome were not altered. Growth 
improved and remained around the mean in the third case. They conclude that genetic 
heterogeneity may determine not only the severity of the disease, but also the therapeutic 
response. 
On the other hand, the American experience has been that after serum creatinine rises 
above approximately 2 - 3  mg/dl, cysteamine is unable to rescue the affected kidney. Thus, 
we would have predicted that the children described in this abstract would not have shown 
a favourable response to cysteamine either in terms of the tubular function or in preserving 
the glomerular function. 
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